Novotech, a global full-service clinical Contract Research Organization (CRO), is pleased to announce its renewal as a Workplace Gender Equality Agency (WGEA) Employer of Choice for Gender Equality (EOCGE) for 2024. This accolade highlights Novotech’s ongoing dedication to maintaining an inclusive and equitable work environment.
The EOCGE certification is a distinguished accolade in Australia, recognizing organizations that excel in gender equality. This voluntary program honors employers who proactively foster environments where all employees, regardless of gender, can succeed.
Novotech is among the 81 companies maintaining this award since 2023. To achieve and retain this certification, employers must demonstrate efforts to close the gender pay gap, develop policies to prevent sex-based harassment and discrimination, and set targets for improving gender equality. They must report their progress every two years.
Dr. John Moller, CEO of Novotech, remarked, “Being re-certified in 2024 underscores our commitment to diversity and inclusion. This achievement reflects the dedication of our entire team to these values. As we expand globally, we are committed to extending these best practices throughout our operations and inspiring positive change in our industry.”
Angela Edwardson, Chief People Officer, added, “Our journey toward gender equality is integral to our corporate culture. The initiatives we’ve implemented as a WGEA Employer of Choice influence our daily operations and strategic decisions, fostering a workplace that supports talent regardless of gender.”
Mary Wooldridge, CEO of WGEA, noted, “EOCGE employers benefit significantly from prioritizing gender equality. Employees are more likely to join and stay with organizations that champion a culture of inclusion. Research shows that businesses with balanced gender representation in leadership roles are more profitable and productive.”
Novotech’s sustained recognition as an EOCGE employer highlights its ongoing commitment to gender equality. As the company continues to grow, its dedication to fostering an inclusive, diverse, and equitable workplace remains central to its values, positively impacting employees’ careers and lives.
The WGEA Employer of Choice for Gender Equality citation solidifies Novotech’s leadership in workplace equality, setting a benchmark for the biotech and CRO sectors both in Australia and internationally.
About Novotech
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) specializing in partnering with biotech companies to advance the development of novel therapeutics. Recognized for its industry-leading contributions, Novotech has won several prestigious awards, including the CRO Leadership Award 2023 and the Asia-Pacific Contract Research Organization Company of the Year Award since 2006. The company offers comprehensive services, including laboratories, Phase I facilities, drug development consulting, and regulatory expertise, with experience in over 5,000 clinical projects. With 34 office locations and over 3,000 professionals worldwide, Novotech is a trusted partner in clinical research.
